James M. Daly - 27 Feb 2025 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Director
Signature
/s/ Mardi Dier, as Attorney-in-Fact
Issuer symbol
MDGL
Transactions as of
27 Feb 2025
Net transactions value
-$4,092,647
Form type
4
Filing time
28 Feb 2025, 16:31:10 UTC
Previous filing
27 Jun 2024
Next filing
02 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Options Exercise $616,118 +9,470 +495% $65.06 11,382 27 Feb 2025 Direct
transaction MDGL Common Stock Options Exercise $666,360 +6,000 +53% $111.06 17,382 27 Feb 2025 Direct
transaction MDGL Common Stock Sale $138,067 -398 -2.3% $346.90 16,984 27 Feb 2025 Direct F1
transaction MDGL Common Stock Sale $4,968,372 -14,302 -84% $347.39 2,682 27 Feb 2025 Direct F2
transaction MDGL Common Stock Sale $268,686 -770 -29% $348.94 1,912 27 Feb 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Stock Option (Right to Buy) Options Exercise $0 -9,470 -100% $0.000000 0 27 Feb 2025 Common Stock 9,470 $65.06 Direct F4
transaction MDGL Stock Option (Right to Buy) Options Exercise $0 -6,000 -100% $0.000000 0 27 Feb 2025 Common Stock 6,000 $111.06 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $346.34 to $347.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $347.36 to $348.225, inclusive.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.73 to $349.705, inclusive.
F4 The shares underlying this option are fully vested and exercisable.